Controversies in Breast Cancer: Use of ctDNA to Tailor Systemic Adjuvant / Post-neoadjuvant Therapies (Part 1)
Mark Pegram, MD
Controversies in Lung Cancer: Neoadjuvant vs Adjuvant IO in Early Stage NSCLC
Luis E. Raez, MD, FACP
Endocrine Therapy for Early -and Late- Stages Breast Cancer: Therapeutic Updates
Joyce O’Shaughnessy, MD
Management of Malignant Hypercalcemia, Bone Metastases & Standard Precautions to Decrease Adverse Events
Meri Muminovic, MD
How to Handle Myelotoxicity from Chemotherapy in 2024: From Colony-Stimulating Factors (CSF) to Agents Providing Myeloprotection to the Three Cell Lines
Martin Dietrich, MD, PhD
